Cardiovascular profile of loratadine

被引：10

作者：

Hey, JA ^{[1
]}

Affrime, M ^{[1
]}

Cobert, B ^{[1
]}

Kreutner, W ^{[1
]}

Cuss, FM ^{[1
]}

机构：

[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

CLINICAL AND EXPERIMENTAL ALLERGY | 1999年 / 29卷

关键词：

loratadine; non-sedating antihistamine; cardiovascular;

D O I：

10.1046/j.1365-2222.1999.0290s3197.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.

引用

页码：197 / 199

页数：3

共 16 条

[1] LORATADINE ADMINISTERED CONCOMITANTLY WITH ERYTHROMYCIN - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC EVALUATIONS [J].

BRANNAN, MD ;

REIDENBERG, P ;

RADWANSKI, E ;

SHNEYER, L ;

LIN, CC ;

CAYEN, MN ;

AFFRIME, MB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (03) :269-278

[2]

BRANNAN MD, 1994, J CLIN PHARMACOL, V34, P1016

[3]

Brannan Melvin D., 1994, Pharmacotherapy, V14, P347

[4] A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME [J].

CURRAN, ME ;

SPLAWSKI, I ;

TIMOTHY, KW ;

VINCENT, GM ;

GREEN, ED ;

KEATING, MT .

CELL, 1995, 80 (05) :795-803

[5] Comparative effects of loratadine and terfenadine on cardiac K+ channels [J].

Ducic, I ;

Ko, CM ;

Shuba, Y ;

Morad, M .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 30 (01) :42-54

[6] ANTIHISTAMINE ACTIVITY, CENTRAL-NERVOUS-SYSTEM AND CARDIOVASCULAR PROFILES OF HISTAMINE H-1 ANTAGONISTS - COMPARATIVE-STUDIES WITH LORATADINE, TERFENADINE AND SEDATING ANTIHISTAMINES IN GUINEA-PIGS [J].

HEY, JA ;

DELPRADO, M ;

CUSS, FM ;

EGAN, RW ;

SHERWOOD, J ;

LIN, CC ;

KREUTNER, W .

CLINICAL AND EXPERIMENTAL ALLERGY, 1995, 25 (10) :974-984

[7]

Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P153

[8] TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].

HONIG, PK ;

WORTHAM, DC ;

ZAMANI, K ;

CONNER, DP ;

MULLIN, JC ;

CANTILENA, LR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518

[9]

Ko CM, 1997, J PHARMACOL EXP THER, V281, P233

[10] Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart [J].

Lacerda, AE ;

Roy, ML ;

Lewis, EW ;

Rampe, D .

MOLECULAR PHARMACOLOGY, 1997, 52 (02) :314-322

← 1 2 →